Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts
The findings reveal both consensus and variability in clinical decision-making for HR+HER2- breast cancer with suspected LN involvement among multinational breast cancer specialists. This underscores the need for enhanced international collaboration and clear guidance in intermediate-risk settings. The incorporation of diagnostic tools such as multigene assays may further support individualized treatment decisions.
Authors
- Sung Gwe Ahn (ORCID: https://orcid.org/0000-0002-8778-9686)
- Yoonwon Kook (ORCID: https://orcid.org/0000-0002-0756-738X)
- Joon Jeong (ORCID: https://orcid.org/0000-0003-0397-0005)
- M.J. Lee
- Henry Gómez (ORCID: https://orcid.org/0000-0003-2660-1843)
- Soong June Bae (ORCID: https://orcid.org/0000-0002-0012-9694)
- Seung Ho Baek (ORCID: https://orcid.org/0000-0003-3681-6506)
Institutions
- Yonsei University (KR)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- Gangnam Severance Hospital (KR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- Journal of Breast Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.4048/jbc.2025.0091
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Great Britain China Centre